Risk Of Upper GI Complications If Gastroprotective Drugs Prescribed With Anti-Inflammatory Medicines Not Taken
To relieve pain, arthritis sufferers are prescribed medications that may include non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors, both of which can irritate the digestive tract. At times additional drugs are co-prescribed with NSAIDs or COX-2 inhibitors to prevent adverse gastrointestinal (GI) effects. Now a new study available in the American College of Rheumatology journal, Arthritis & Rheumatism, reveals that decreasing gastroprotective agent (GPA) adherence among users of COX-2 inhibitors is linked to an increased risk of such upper GI complications. Current clinical guidelines recommend that GPAs, such as proton pump inhibitors (PPIs) or misoprostol, be prescribed to patients taking NSAIDs and COX-2 inhibitors - also known as COX-2 blockers - who are at high risk of upper GI events.
Glucocorticoid-Induced Osteoporosis: Management Strategies To Prevent Bone Loss And Related Fractures In High-Risk Patients
Oral glucocorticoids are commonly prescribed for a wide variety of disorders, most commonly for rheumatoid arthritis, obstructive pulmonary disease and inflammatory bowel diseases. However, the use of these medications can result in rapid bone loss during the first three to six months of therapy, leading to increased risk of fragility fractures. Although awareness of glucocorticoid-induced osteoporosis (GIO) has grown in recent years, it still remains vastly under-diagnosed and under-treated. As a result, and despite the availability of effective treatment options to reduce the risk of fractures, millions of patients around the world are left at risk of potentially serious fractures. In an effort to address this serious problem, the International Osteoporosis Foundation (IOF) and the European Calcified Tissue Society (ECTS) have published a guidance document* which provides a framework for the development of national assessment and treatment guidelines.
New research shows it may be no accident when doctors observe how patients suffering from both breast cancer and arthritis seem to have more aggressive cancer. However, the new-found interaction between the two diseases may also suggest a possible treatment. A potential relationship between metastatic breast cancer and autoimmune arthritis, as suggested by past epidemiological studies, has led researchers from the University of North Carolina at Charlotte to perform a series of mouse model experiments that appear to confirm the connection. "Epidemiological studies have implied that breast cancer survival is significantly lower in patients who also had autoimmune arthritis, " noted Pinku Mukherjee, Irwin Belk Distinguished Scholar of Cancer Research at UNC Charlotte, whose lab conducted the experiments.
According to UCB, certolizumab pegol achieved top-level results in a phase 3 study, which assessed the drug's efficacy and safety in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases, including ankylosing spondylitis (AS). Professor Dr Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President at UCB explained: "The population in this study included both patients with AS and with an early stage of the disease, called non-radiographic axial spondyloarthritis. Both populations are part of a recently defined group of rheumatic diseases, axial spondyloarthritis. The positive top-line results are very encouraging since there is a need for treatments for patients with non-radiographic AxSpA and for additional effective anti-TNF treatments for AS.
Gene That Encodes Crucial Pain Receptor May Be Key To Individualizing Therapy For Major Health Problem
Nearly one in five people suffers from the insidious and often devastating problem of chronic pain. That the problem persists, and is growing, is striking given the many breakthroughs in understanding the basic biology of pain over the past two decades. A major challenge for treating chronic pain is to understand why certain people develop pain while others, with apparently similar disorders or injuries, do not. An equally important challenge is to develop individualized therapies that will be effective in specific patient populations. Research published online in Nature Medicine points to solutions to both challenges. A research team led by Prof. Jeffrey Mogil of McGill University in Montreal and Prof. Michael Salter of The Hospital for Sick Children (SickKids), affiliated with the University of Toronto, has identified a major gene affecting chronic pain sensitivity.